Skip to content

Gross margin at other companies

HRO
HarrowHROW
74.1%-0.4pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
86.1%+7.2pp
XER
Xeris Biopharma Holdings, Inc.XERS
85.9%+3.7pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
60.8%+1.5pp
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
150%-15.6pp
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
86%-0.2pp

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K
Free cash flow$7.3M+251%

Valuation

See full
Market cap$930.79M+156%
Enterprise value$942.39M+150%
P/S10.7×+3.2×

Profitability

See full
Operating margin-15.1%
Net margin-9.5%-2.7pp
FCF margin17.1%

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity-0.2×
Current ratio1.2×-0.8×

Where this comes from

Calculated from Eton Pharmaceuticals, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s gross margin?
Eton Pharmaceuticals, Inc. (ETON) reported gross margin of 54.8% in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s gross margin changed year-over-year?
Eton Pharmaceuticals, Inc.'s gross margin decreased by 6.4% year-over-year, from 58.5% to 54.8%.
What is the long-term trend for Eton Pharmaceuticals, Inc.'s gross margin?
Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s gross margin has grown at a -49.8% compound annual growth rate (CAGR), from -1,684.6% to 53.5%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.